The Blood Test That’s About to Change Colorectal Cancer Screening for 90 Million Americans

Carelon’s coverage decision puts Guardant Health’s Shield test in front of Blue Cross Blue Shield plans in 26 states. Here’s what the clinical data actually says.

On September 1, Carelon Health Services quietly updated its clinical guidelines to cover Guardant Health’s Shield blood test for colorectal cancer screening. If you missed it, you’re not alone — coverage announcements rarely make headlines. But this one should.

Carelon is the specialty benefits management arm for Blue Cross Blue Shield plans across 26 states, including California, New York, Texas, and Illinois. The effective date is November 15. Because UnitedHealth Group already moved first in August — adding Shield to coverage for its roughly 40 million commercial members — the Carelon announcement pushes the total number of Americans with access to Shield-based colorectal cancer screening to approximately 90 million.

That number is going to keep climbing. Cigna’s EviCore by Evernorth has already announced coverage effective January 1, 2027. Medicare started covering Shield after the FDA approved it as a primary screening modality in 2024. By this time next year, the question won’t be…